File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Gamma-tocotrienol as an effective agent in targeting prostate cancer stem cell-like population

TitleGamma-tocotrienol as an effective agent in targeting prostate cancer stem cell-like population
Authors
KeywordsProstate cancer
Stem cell
Tocotrienol
Vitamin E
Issue Date2011
PublisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www3.interscience.wiley.com/journal/29331/home
Citation
International Journal Of Cancer, 2011, v. 128 n. 9, p. 2182-2191 How to Cite?
AbstractEmerging evidence supports that prostate cancer originates from a rare subpopulation of cells, namely prostate cancer stem cells (CSCs). Conventional therapies for prostate cancer are believed to mainly target the majority of differentiated tumor cells but spare CSCs, which may account for the subsequent disease relapse after treatment. Therefore, successful elimination of CSCs may be an effective strategy to achieve complete remission from this disease. Gamma-tocotrienols (γ-T3) is one of the vitamin-E constituents, which have been shown to have anticancer effects against a wide range of human cancers. Recently, we have reported that γ-T3 treatment not only inhibits prostate cancer cell invasion but also sensitizes the cells to docetaxel-induced apoptosis, suggesting that γ-T3 may be an effective therapeutic agent against advanced stage prostate cancer. Here, we demonstrate for the first time that γ-T3 can downregulate the expression of prostate CSC markers (CD133/CD44) in androgen-independent prostate cancer cell lines (PC-3 and DU145), as evident from Western blotting analysis. Meanwhile, the spheroid formation ability of the prostate cancer cells was significantly hampered by γ-T3 treatment. In addition, pretreatment of PC-3 cells with γ-T3 was found to suppress tumor initiation ability of the cells. More importantly, although CD133-enriched PC-3 cells were highly resistant to docetaxel treatment, these cells were as sensitive to γ-T3 treatment as the CD133-depleted population. Our data suggest that γ-T3 may be an effective agent in targeting prostate CSCs, which may account for its anticancer and chemosensitizing effects reported in previous studies. © 2010 UICC.
Persistent Identifierhttp://hdl.handle.net/10722/148636
ISSN
2015 Impact Factor: 5.531
2015 SCImago Journal Rankings: 2.657
ISI Accession Number ID
Funding AgencyGrant Number
QUT
HKU
Vice Chancellor research fellowship
Funding Information:

Grant sponsor: HKU Seed funding for applied research, M. T. L is supported by QUT Vice Chancellor Research Fellowship.

References

 

DC FieldValueLanguage
dc.contributor.authorLuk, SUen_HK
dc.contributor.authorYap, WNen_HK
dc.contributor.authorChiu, YTen_HK
dc.contributor.authorLee, DTWen_HK
dc.contributor.authorMa, Sen_HK
dc.contributor.authorLee, TKWen_HK
dc.contributor.authorVasireddy, RSen_HK
dc.contributor.authorWong, YCen_HK
dc.contributor.authorChing, YPen_HK
dc.contributor.authorNelson, Cen_HK
dc.contributor.authorYap, YLen_HK
dc.contributor.authorLing, MTen_HK
dc.date.accessioned2012-05-29T06:14:15Z-
dc.date.available2012-05-29T06:14:15Z-
dc.date.issued2011en_HK
dc.identifier.citationInternational Journal Of Cancer, 2011, v. 128 n. 9, p. 2182-2191en_HK
dc.identifier.issn0020-7136en_HK
dc.identifier.urihttp://hdl.handle.net/10722/148636-
dc.description.abstractEmerging evidence supports that prostate cancer originates from a rare subpopulation of cells, namely prostate cancer stem cells (CSCs). Conventional therapies for prostate cancer are believed to mainly target the majority of differentiated tumor cells but spare CSCs, which may account for the subsequent disease relapse after treatment. Therefore, successful elimination of CSCs may be an effective strategy to achieve complete remission from this disease. Gamma-tocotrienols (γ-T3) is one of the vitamin-E constituents, which have been shown to have anticancer effects against a wide range of human cancers. Recently, we have reported that γ-T3 treatment not only inhibits prostate cancer cell invasion but also sensitizes the cells to docetaxel-induced apoptosis, suggesting that γ-T3 may be an effective therapeutic agent against advanced stage prostate cancer. Here, we demonstrate for the first time that γ-T3 can downregulate the expression of prostate CSC markers (CD133/CD44) in androgen-independent prostate cancer cell lines (PC-3 and DU145), as evident from Western blotting analysis. Meanwhile, the spheroid formation ability of the prostate cancer cells was significantly hampered by γ-T3 treatment. In addition, pretreatment of PC-3 cells with γ-T3 was found to suppress tumor initiation ability of the cells. More importantly, although CD133-enriched PC-3 cells were highly resistant to docetaxel treatment, these cells were as sensitive to γ-T3 treatment as the CD133-depleted population. Our data suggest that γ-T3 may be an effective agent in targeting prostate CSCs, which may account for its anticancer and chemosensitizing effects reported in previous studies. © 2010 UICC.en_HK
dc.languageengen_US
dc.publisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www3.interscience.wiley.com/journal/29331/homeen_HK
dc.relation.ispartofInternational Journal of Canceren_HK
dc.subjectProstate canceren_HK
dc.subjectStem cellen_HK
dc.subjectTocotrienolen_HK
dc.subjectVitamin Een_HK
dc.subject.meshAnimalsen_US
dc.subject.meshAntineoplastic Agents - Pharmacologyen_US
dc.subject.meshBlotting, Westernen_US
dc.subject.meshCell Line, Tumoren_US
dc.subject.meshChromans - Pharmacologyen_US
dc.subject.meshHumansen_US
dc.subject.meshMaleen_US
dc.subject.meshMiceen_US
dc.subject.meshMice, Nudeen_US
dc.subject.meshNeoplastic Stem Cells - Drug Effects - Pathologyen_US
dc.subject.meshProstatic Neoplasms - Pathologyen_US
dc.subject.meshVitamin E - Analogs & Derivatives - Pharmacologyen_US
dc.subject.meshXenograft Model Antitumor Assaysen_US
dc.titleGamma-tocotrienol as an effective agent in targeting prostate cancer stem cell-like populationen_HK
dc.typeArticleen_HK
dc.identifier.emailMa, S:sma@pathology.hku.hken_HK
dc.identifier.emailLee, TKW:tkwlee@hkucc.hku.hken_HK
dc.identifier.emailWong, YC:ycwong@hkucc.hku.hken_HK
dc.identifier.emailChing, YP:ypching@hku.hken_HK
dc.identifier.emailLing, MT:patling@hkucc.hku.hken_HK
dc.identifier.authorityMa, S=rp00506en_HK
dc.identifier.authorityLee, TKW=rp00447en_HK
dc.identifier.authorityWong, YC=rp00316en_HK
dc.identifier.authorityChing, YP=rp00469en_HK
dc.identifier.authorityLing, MT=rp00449en_HK
dc.description.naturelink_to_OA_fulltexten_US
dc.identifier.doi10.1002/ijc.25546en_HK
dc.identifier.pmid20617516-
dc.identifier.scopuseid_2-s2.0-79952463186en_HK
dc.identifier.hkuros201804-
dc.identifier.hkuros203130-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-79952463186&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume128en_HK
dc.identifier.issue9en_HK
dc.identifier.spage2182en_HK
dc.identifier.epage2191en_HK
dc.identifier.isiWOS:000288176600019-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridLuk, SU=36981977600en_HK
dc.identifier.scopusauthoridYap, WN=25637949100en_HK
dc.identifier.scopusauthoridChiu, YT=23975797700en_HK
dc.identifier.scopusauthoridLee, DTW=15747521900en_HK
dc.identifier.scopusauthoridMa, S=16444895800en_HK
dc.identifier.scopusauthoridLee, TKW=7501439435en_HK
dc.identifier.scopusauthoridVasireddy, RS=35489634200en_HK
dc.identifier.scopusauthoridWong, YC=7403041798en_HK
dc.identifier.scopusauthoridChing, YP=7005431277en_HK
dc.identifier.scopusauthoridNelson, C=7403704008en_HK
dc.identifier.scopusauthoridYap, YL=7005551975en_HK
dc.identifier.scopusauthoridLing, MT=7102229780en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats